NervGen Pharma Corp. (NASDAQ: NGEN) announced results from independent, blinded biomechanical gait analyses of its drug candidate NVG-291 in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE